| Tumors Derived from Langerhans Cells studied in …STUDIED_INderived10 of 27show all (up to 200) |
|---|
| → studied in | NCT03210714Phase 2 · active not recruiting Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03698994Phase 2 · active not recruiting Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02402244recruiting Project: Every Child for Younger Patients With Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (14 active) | — | — | Childhood Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07440290Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. · condition mapped ONTOLOGY_EXACT · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05028621NA · suspended Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease · condition mapped ONTOLOGY_EXACT · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04320888Phase 2 · active not recruiting Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial · condition mapped CURATED_BROADER · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02523040Phase 2 · active not recruiting Lenalidomide for Adult Histiocyte Disorders · condition mapped ONTOLOGY_EXACT · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04284774Phase 2 · active not recruiting Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial · condition mapped CURATED_BROADER · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03213652Phase 2 · active not recruiting Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 27 trials mapped (14 active) | — | — | Langerhans Cell Histiocytosis | 1 | Observed | clinicaltrials | graph → |